openPR Logo
Press release

CDK Inhibitors Therapeutics Pipeline Analysis 2017

08-29-2017 09:53 AM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.

Explore Report at: www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis

USFDA granted Breakthrough Therapy Designation to a drug candidate of Eli Lilly and Company which is being developed for the treatment of refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This will facilitate the development and expedite the review of drug candidate for the treatment of refractory HR+ advanced or metastatic breast cancer.

Eli Lilly and Company and Boehringer Ingelheim GmbH entered into a collaboration for clinical studies of their drug candidates in combination, in patients diagnosed with HR+, HER2-metastatic breast cancer.

Explore Report Sample at: www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis/report-sample

Some of the key players developing drugs as CDK inhibitors for the treatment of various indications include Eli Lilly and Company, Merck & Co., AstraZeneca plc and others.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-Free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CDK Inhibitors Therapeutics Pipeline Analysis 2017 here

News-ID: 687649 • Views:

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for CDK

Investigation ongoing for Investors in CDK Global, Inc. (NASDAQ: CDK) over poten …
An investigation on behalf of investors in shares of CDK Global, Inc. (NASDAQ: CDK) was announced over potential breaches of fiduciary duties by certain officers and directors at CDK Global, Inc. Investors who purchased shares of CDK Global, Inc. (NASDAQ: CDK) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain CDK Global, Inc. directors breached
Cancer CDK Inhibitors Market 2021 | Detailed Report
According to Market Study Report, Cancer CDK Inhibitors Market provides a comprehensive analysis of the Cancer CDK Inhibitors Market segments, including their dynamics, size, growth, regulatory requirements, competitive landscape, and emerging opportunities of global industry. An exclusive data offered in this report is collected by research and industry experts team. Get Free Sample PDF (including full TOC, Tables and Figures) of Cancer CDK Inhibitors Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5087783 The report provides a
CDK Websites See Significant Organic Traffic Increases
REUNION MARKETING Data Beats Intuition 418 S. Dawson St. Raleigh, North Carolina 27601 NEWS RELEASE For Immediate Release CDK Websites See Significant Organic Traffic Increases The Recent Google Algorithm Affected Traffic Flows Across CMSs August 20, 2018 — Reunion Marketing personnel noted a remarkable increase in organic traffic for CDK websites that directly coincides with a Google algorithm update. While conducting regular audits, members of the Reunion team discovered a pattern of significant increases in organic website traffic throughout
Dealer Management Market Excellent Growth | IBM, CA, Cox Automotive, CDK Global
The qualitative research study conducted by HTF MI titled “Global Dealer Management Market Size, Status and Forecast 2025” provides primary Data, surveys, Scope of the Product and vendor briefings. The market dynamic forces have been determined after conducting a detailed study of the Global Dealer Managementmarket. The study provides forecasts for Dealer Management investments till 2022. If you are involved in the Dealer Management industry or intend to be, then
Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022 Report
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report highlights: * Selectivity and Working Mechanism of a Cancer CDKs Inhibitor * Recent Advances in the CDKs Related Cancer Therapy * Global Cancer CDK Inhibitors Clinical Trials Insight: 45 Drugs in Pipeline * Market Opportunity Assessment: More Than US$ 20 Billion (2022) * Price Analysis of Cancer CDKs Inhibitors: * Sales Analysis of Available Drugs: More Than US$ 2 Billion (2017) Download Report Sample Weblink:
Download Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022
“Global Cancer CDK Inhibitors Market and Clinical Pipeline Outlook 2022” report gives comprehensive insight on clinical and non-clinical parameters related to emergence and growth of CDK inhibitors in cancer therapy. As per report findings, CDK inhibitors have emerged as new growth frontier for the organizations involved in the research, development, licensing and commercialization of targeted cancer therapies. There are 2 CDK inhibitors commercially available in the market for the treatment